Pulse ·
Low-dose Zoladex exits Australia's PBS in November
AstraZeneca has announced that low-dose Zoladex (goserelin 3.6 mg, the monthly implant) will be withdrawn from Australia's Pharmaceutical Benefits Scheme from 1 November 2026, for commercial reasons unrelated to safety or efficacy. About 100,000 Australians fill this prescription annually — many of them women being treated for endometriosis or hormone receptor-positive breast cancer.
The 10.8 mg three-monthly formulation will remain available and AstraZeneca is seeking PBS listing for it across breast cancer indications. Alternative hormonal therapies exist for both conditions. With a five-month transition window, the time to speak with your GP or specialist is now, not October.
AstraZeneca confirmed this week that monthly Zoladex — goserelin 3.6 mg — will be removed from the Pharmaceutical Benefits Scheme on 1 November 2026. The stated reason: commercial, entirely unrelated to safety or efficacy.
For the people affected, that distinction offers thin comfort. If you’re managing endometriosis pain, or you’re a pre-menopausal woman using this implant to suppress oestrogen and reduce your risk of breast cancer recurrence, “commercially unviable” is not a category that has meaning for your body. That is a legitimate thing to feel angry about.
What Zoladex actually does
Goserelin is a GnRH (gonadotrophin-releasing hormone) analogue — a synthetic compound that tells the pituitary gland to stop signalling the ovaries to produce oestrogen, or the testes to produce testosterone. For women with endometriosis, this hormonal suppression reduces the activity of endometrial tissue growing outside the uterus and can meaningfully reduce pain. For pre-menopausal women with hormone receptor-positive (HR+) breast cancer, oestrogen suppression is part of adjuvant treatment strategy — altering the hormonal environment in which the cancer grew.
About 100,000 prescriptions for the monthly formulation are dispensed annually in Australia, and a newsGP poll found that 57% of GPs already have patients affected by this decision. The 10.8 mg three-monthly formulation — currently used primarily for prostate cancer — will continue. AstraZeneca is seeking PBS listing for the three-monthly dose in breast cancer, which would preserve subsidised access, but that listing is not yet confirmed.
Both-and
There are alternatives. For breast cancer management, oncologists have access to a wide range of adjuvant hormonal regimens, and more than 90 treatment combination options exist across the full breast cancer pathway. For endometriosis, other GnRH analogues including leuprorelin and triptorelin are available and may suit many patients making the switch. The clinical landscape is not barren. This is important to say clearly so it doesn’t get lost.
And yet the transition burden is real, and deserves equal weight. Five months is a short window in clinical time — particularly in oncology, where specialist appointment availability is already strained, and particularly when this announcement falls across end-of-year holidays. For the individual patient, a small percentage reduction in recurrence risk is not experienced as a statistical abstraction. It is a reason to stay on the medication. The distress that comes with uncertainty — will the three-monthly PBS listing come through in time? — is clinically meaningful even when the underlying pharmacology remains sound.
One patient cited in the newsGP piece — a 30-year-old breast cancer patient — put it plainly: to make the withdrawal announcement without the three-monthly PBS alternative confirmed “is just so traumatic.” That response is not disproportionate. It reflects what it feels like to have your treatment continuity decided by a commercial boardroom with no visibility into your care.
There is also a structural point worth making. Australia accounts for just 2.1% of global pharmaceutical demand. Commercial decisions made at global scale routinely affect access here in ways that are difficult to anticipate and impossible for individual patients or GPs to prevent. This is not the first time a medication has been discontinued for Australian commercial reasons while remaining available elsewhere; it will not be the last. That pattern is a health policy problem, not a clinical one, and it belongs on the table for health systems leadership.
My two cents
If you are currently on monthly Zoladex, make an appointment with your GP or specialist in the next few weeks. Not in September when the November deadline is loud. Key questions worth raising now:
Is the three-monthly formulation a clinically appropriate option for your situation? If so, when can the transition be arranged? Is the PBS listing for three-monthly goserelin across breast cancer indications confirmed, and if not, what is the timeline and what does the gap look like?
For endometriosis management specifically, this is also a reasonable moment to review whether your overall care plan is as robust as it could be. Endometriosis care in Australia has well-documented continuity gaps even in stable supply conditions. If your only specialist touchpoint is the prescribing script, strengthening that relationship now is worthwhile beyond the immediate medication question.
For GPs reading this: with 57% of practices already carrying affected patients and a November deadline, proactive recalls are appropriate. This is early enough to act without urgency turning into panic.
Verdict: yes — worth knowing about, and worth acting on well before October.